Dose groups—lymphodepletion and cell doses
| Dose group | Lymphodepleting chemotherapy | Transduced ADP-A2M10 (range) | Patient ID |
| 1 | Cyclophosphamide 1800 mg/m2/day on days −7 and –6 | 0.1×109 (0.08×109–0.12×109) | 1–5 |
| 2 | Cyclophosphamide 600 mg/m2/day and fludarabine 30 mg/m2/day on days –7, –6, and –5 | 1.0×109 (0.5×109–1.2×109) | 6–8 |
| 3 | Cyclophosphamide 600 mg/m2/day on days –7, –6, and –5, and fludarabine 30 mg/m2/day on days –7, –6, –5, and –4 | 5.0×109 (1.2×109–6×109) | 9–10 |
| Expansion group | Cyclophosphamide 1800 mg/ m2/day on days –3 and –2, and fludarabine 30 mg/m2/day on days –5, –4, –3, and –2 | 5.0×109 (1.2×109–15×109) | 9* |
| Cyclophosphamide 600 mg/m2/day on days –7, –6, and –5, and fludarabine 30 mg/m2/day on days –7, –6, –5, and –4 | 5.0×109 (1.2×109–15×109) | 11 |
*One patient (patient 9) received a second infusion at this schedule of cyclophosphamide and fludarabine and ADP-A2M10.
ID, identifier.